FHFatma Hacet

Fatma Hacet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatma Hacet has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A mini review: the trio of artichoke ( Cynara scolymus L. ), cytotoxicity, and apoptosis

    by Taygun Dayi, Müjgan Kuşi, Fatma Hacet

    The artichoke, also known as C scolymus L. , is an edible plant that is commonly grown worldwide, particularly in the Mediterranean region. C scolymus L . has different nutritious by-products , and while it depends on the culture, nearly all of them are consumable. Cancer is the second leading cause of death worldwide, and many molecular pathways are effective in both the development and prevention of cancer. This narrative article aims to review the effects of C scolymus L . on cytotoxicity and apoptosis, also known as programmed cell death. Current in vitro studies published in the last decade have shown that different by-products of C scolymus L. extracts increase cytotoxicity, which is the specific destructive action of an agent on cancer cells, and may also induce apoptosis. Moreover, C scolymus L . causes the stimulation of pro-apoptotic and suppression of anti-apoptotic cancer pathways. It increases initiating caspases 8 and 10 activities in the extrinsic pathway of apoptosis. While different C scolymus L. extracts potentially increase Bax expression, they suppress Bcl-2 in the intrinsic pathway of apoptosis. These effects cause an increase in caspase 9 activity. Increased activities of these initiating caspases (8-9-10) stimulate effector caspases 3 and 7, thus apoptosis. These are important beneficial effects for apoptosis and thus preventing cancer. However, these potential effects are limited to the results of in vitro studies. More in vitro studies on different cancer cell lines, in vivo studies, and randomised controlled human trials are therefore necessary to increase the level of evidence.


  • Open Access

    Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in an in vitro Alzheimer’s Disease Model

    by Fatma Hacet, Eda Becer, Hafize Seda Vatansever, Sevinç Yücecan

    Background: This study aimed to establish an in vitro model of Alzheimer’s Disease (AD) to investigate the neuroprotective activities of allyl isothiocyanate (AITC) and sulforaphane (SFN). Materials and Methods: Human neuroblastoma cell lines (SKNAS) were used for the in vitro model of AD after amyloid-β25−35 (Aβ25–35) treatment. Cytotoxicity analysis was performed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Indirect immunocytochemical methods were used to assess the tau protein, alpha-synuclein (α-synuclein), and β-amyloid distribution in the in vitro model of AD and SKNAS cells. Results: An in vitro AD model was induced by treatment of SKNAS cells with 1 µM of Aβ25–35 for 48 h. AITC and SFN were applied for 48 h, and the optimal concentrations were determined as 50 µM AITC and 15 µM SFN. Reduced tau immunoreactivity was shown after AITC and SFN administration in SKNAS cells and in vitro models, demonstrating that AITC and SFN prevented amyloid plaque production in the in vitro AD model control group by reducing the β-amyloid level, α-synuclein levels were similar in control and in vitro AD model cells. Reduced α-synuclein levels were observed after SFN treatment in the AD model cells and AITC treatment in the control cells. Conclusion: It could be concluded that AITC and SFN are potential components as neuroprotective agents against AD.